listeo-data-scraper domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/healingmaps.imarkdev.com/wp-includes/functions.php on line 6170
The Oregon Health Authority wanted $20,000 annual licenses. Community surveys suggested enough licensees would quit that the state would collect less than it does today.
Read More
A proposed rule would place five tryptamines into Schedule I. It is the second attempt at the same action, and comments close October 23.
Read More
Diligence is unglamorous. Nine things acquirers actually look at in a ketamine practice, from accrual books and payer contracts to outcomes data and chair utilization.
Read More
Israeli MDMA trials run 15 sessions over three to four months, including an eight hour dosing day with two therapists present. The staffing math is the part US clinics should be reading.
Read More
A new letter in npj Mental Health Research argues a 2024 meta-analysis compared ketamine and psilocybin with different instruments. Across the same ketamine studies, one scale explains 3 percent of outcomes and another explains 15 percent.
Read More
Higher dissociation scores went with better depression outcomes on subcutaneous esketamine, with derealization driving the difference. The study was small, open label and exploratory.
Read More
Collecting PHQ-9 scores is common. Being able to state a response rate, and send it back to the referring clinician, is not. That gap is where referrals, payer talks and exit value live.
Read More
From FDA's October 5 psychedelics docket to the DEA telehealth expiration and Medicare's 2027 in-person rule, six dates every ketamine clinic should plan around.
Read More
Oxford found ketamine quieted the habenula 24 hours after infusion. A Texas A&M analysis linked 24-hour brain changes in older veterans to day-7 improvement.
Read More
ARPA-H's ASCENT-IBO program funds Phase 1 and 2 ibogaine trials for opioid use disorder, with patient safety up front. Solution summaries are due October 15.
Read More